GPS2 and metabolic dysfunction-associated steatohepatitis: In conclusion, our study identifies GPS2 as an epigenome modifier and PPARα-selective corepressor in hepatocytes whose inhibition has the therapeutic potential to reverse the progression of NASH toward fibrosis.